Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID21948594.edit
Griswold DE, Webb EF, Breton J, White JR, Marshall PJ, Torphy TJ. (1993). „Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response”. Inflammation17 (3): 333–44. DOI:10.1007/BF00918994. PMID7687237.
Wachtel H. (1983). „Potential antidepressant activity of rolipram and other selective cyclic adenosine 3',5'-monophosphate phosphodiesterase inhibitors”. Neuropharmacology22 (3): 267–72. DOI:10.1016/0028-3908(83)90239-3. PMID6302550.
Maxwell CR, Kanes SJ, Abel T, Siegel SJ. (2004). „Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications”. Neuroscience129 (1): 101–7. DOI:10.1016/j.neuroscience.2004.07.038. PMID15489033.
Kanes SJ, Tokarczyk J, Siegel SJ, Bilker W, Abel T, Kelly MP. (2006). „Rolipram: A specific phosphodiesterase 4 inhibitor with potential antipsychotic activity”. Neuroscience144 (1): 239–46. DOI:10.1016/j.neuroscience.2006.09.026. PMID17081698.
Lelkes Z, Alföldi P, Erdos A, Benedek G. (1998). „Rolipram, an antidepressant that increases the availability of cAMP, transiently enhances wakefulness in rats”. Pharmacology, Biochemistry and Behaviour60 (4): 835–9. DOI:10.1016/S0091-3057(98)00038-0. PMID9700966.
Nikulina, E. (2004-06-08). „The Phosphodiesterase Inhibitor Rolipram Delivered after a Spinal Cord Lesion Promotes Axonal Regeneration and Functional Recovery”. Proceedings of the National Academy of Sciences of the United States101: 8786. DOI:10.1073/pnas.0402595101. JSTOR3372336.
MF, Beal; Cleren C, Calingasan NY, Yang L, Klivenyi P, Lorenzl S (2005). „Oxidative Damage in Parkinson's Disease”. U.S. Army Medical Research and Materiel CommandFort Detrick, Maryland 21702-5012. Arhivirano iz originala na datum 2012-05-23. Pristupljeno 13. 11. 2009.
Nikulina, E. (2004-06-08). „The Phosphodiesterase Inhibitor Rolipram Delivered after a Spinal Cord Lesion Promotes Axonal Regeneration and Functional Recovery”. Proceedings of the National Academy of Sciences of the United States101: 8786. DOI:10.1073/pnas.0402595101. JSTOR3372336.
Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID21948594.edit
Griswold DE, Webb EF, Breton J, White JR, Marshall PJ, Torphy TJ. (1993). „Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response”. Inflammation17 (3): 333–44. DOI:10.1007/BF00918994. PMID7687237.
Bobon D, Breulet M, Gerard-Vandenhove MA, Guiot-Goffioul F, Plomteux G, Sastre-y-Hernandez M, Schratzer M, Troisfontaines B, von Frenckell R, Wachtel H. (1988). „Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double blind double-dummy study between rolipram and desipramine in hospitalized major and/or endogenous depressives”. Eur Arch Psychiatry Neurol Sci238 (1): 2–6. PMID3063534.
Wachtel H. (1983). „Potential antidepressant activity of rolipram and other selective cyclic adenosine 3',5'-monophosphate phosphodiesterase inhibitors”. Neuropharmacology22 (3): 267–72. DOI:10.1016/0028-3908(83)90239-3. PMID6302550.
Maxwell CR, Kanes SJ, Abel T, Siegel SJ. (2004). „Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications”. Neuroscience129 (1): 101–7. DOI:10.1016/j.neuroscience.2004.07.038. PMID15489033.
Kanes SJ, Tokarczyk J, Siegel SJ, Bilker W, Abel T, Kelly MP. (2006). „Rolipram: A specific phosphodiesterase 4 inhibitor with potential antipsychotic activity”. Neuroscience144 (1): 239–46. DOI:10.1016/j.neuroscience.2006.09.026. PMID17081698.
Lelkes Z, Alföldi P, Erdos A, Benedek G. (1998). „Rolipram, an antidepressant that increases the availability of cAMP, transiently enhances wakefulness in rats”. Pharmacology, Biochemistry and Behaviour60 (4): 835–9. DOI:10.1016/S0091-3057(98)00038-0. PMID9700966.
MF, Beal; Cleren C, Calingasan NY, Yang L, Klivenyi P, Lorenzl S (2005). „Oxidative Damage in Parkinson's Disease”. U.S. Army Medical Research and Materiel CommandFort Detrick, Maryland 21702-5012. Arhivirano iz originala na datum 2012-05-23. Pristupljeno 13. 11. 2009.